Laser capture microdissection: techniques and applications in liver diseases

被引:0
作者
Beatriz Aguilar-Bravo
Pau Sancho-Bru
机构
[1] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
[2] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd),undefined
来源
Hepatology International | 2019年 / 13卷
关键词
Laser capture microdissection; Liver diseases; Tissue preservation; Transcriptome; Proteome; Downstream analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Routine transcriptomic and proteomic analysis are usually performed at a whole organ or tissue level. These approaches provide an average readout of all cell types present within the tissue but do not allow differentiating the profile of specific cell populations. Laser capture microdissection (LCM) constitutes an excellent tool to isolate cell populations or areas of interest within a tissue. By direct visualization, the selected area is excised by a laser and can be further processed for a variety of downstream analyses. This technology has been widely used in the study of liver diseases, from DNA and RNA sequencing to mass spectrometry. However, LCM also has important limitations. To ensure the best integrity of the molecule of interest, optimal tissue preservation, careful tissue sectioning, and optimization of the staining procedure are required. The present review provides a description of the LCM technology, including tips and technical recommendations to perform the procedure, as well as an overview of studies using LCM technology in the field of liver disease.
引用
收藏
页码:138 / 147
页数:9
相关论文
共 269 条
[41]  
Hanson NE(2009)The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma J Hepatol 50 358-630
[42]  
Tang X(2012)Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 142 e15-108
[43]  
Fujimoto J(2013) and Cancer 119 1669-undefined
[44]  
Rodriguez-Canales J(2013) mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas Hepatology 58 1992-undefined
[45]  
Tangrea MA(2017)Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma Ann Surg Oncol 24 2344-undefined
[46]  
Mukherjee S(2018)Micro-RNA-130a-3p regulates gemcitabine resistance via PPARG in cholangiocarcinoma Oncol Rep 40 1621-undefined
[47]  
Gao B(2013)Overexpression of miR-221 and miR-222 in the cancer stroma is associated with malignant potential in colorectal cancer Cancer Sci 104 624-undefined
[48]  
Markey SP(2017)Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis Br J Cancer 117 1360-undefined
[49]  
Du Q(1996)Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis Adv Cancer Res 68 67-undefined
[50]  
Armani M(undefined)Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer undefined undefined undefined-undefined